title: Combined treatment of tetrahydrocurcumin and chlorogenic acid exerts potential antihyperglycemic effect on streptozotocin-nicotinamide-induced diabetic rats.
abstract: We have shown that separate dose of tetrahydrocurcumin (THC) at a dose of 80 mg/kg body weight (b.w.) and chlorogenic acid (CGA) at a dose of 5 mg/kg b.w. exerts antidiabetic potential in streptozotocin (STZ) (45 mg/kg b.w.) nicotinamide induced diabetic rats. In the present study we have attempted to compare the antihyperglycemic activity exerted by the combined treatment of THC/CGA with THC and CGA alone treated diabetic rats. After the experimental period of 45 days we observed that supplementation with combined dose of THC/CGA significantly decreased glycosylated hemoglobin (HbA(1C)) and increased the levels of plasma insulin, C-peptide, hemoglobin and glycogen which were decreased upon STZ treatment and also significantly reversed the altered activities of gluconeogenic enzymes such as glucose-6-phosphatase, fructose-1,6-bisphosphatase, and of glycolytic enzymes such as glucokinase and hexokinase in the tissues of experimental rats as compared to their individual supplementation. Thus our results substantiate that though THC and CGA alone found to exert hypoglycemic activity the maximum hypoglycemic effect was always observed in diabetic rats treated THC/CGA and this summed effect seems to have a promising value for the development of a potent phytomedicine for diabetes.
authors.affiliation: Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalai Nagar, Tamil Nadu, India.
authors.forename: Krishnamoorthy
authors.initials: K
authors.lastname: Karthikesan
authors.forename: Leelavinothan
authors.initials: L
authors.lastname: Pari
authors.forename: Venugopal P
authors.initials: VP
authors.lastname: Menon
mesh_terms: D000818:Animals; D002726:Chlorogenic Acid / Q000008:administration & dosage*; D003474:Curcumin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000139:chemically induced / Q000188:drug therapy*; D004338:Drug Combinations; D005240:Feasibility Studies; D006003:Glycogen / Q000097:blood*; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000097:blood*; D008297:Male; D009536:Niacinamide; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects; D013311:Streptozocin; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D007004:Hypoglycemic Agents; D007328:Insulin; C096277:tetrahydrocurcumin; D009536:Niacinamide; D002726:Chlorogenic Acid; D013311:Streptozocin; D006003:Glycogen; D003474:Curcumin